Reviewer’s report

Title: High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival.

Version: 0 Date: 29 Sep 2016

Reviewer: Che Li

Reviewer's report:

In this manuscript, Baongoc Nasri et. al described the high expression of EphA3 may play a role in metastasis and worse survival in gastric adenocarcinoma patients. Their data are potentially interesting and it will bring therapeutic potential for cancer treatment. But the paper needs to be resubmitted to the journal after revision though the study has an important potent clinic application for gastric cancer.

Several issues need to be addressed:

1. Do you have cell culture experiment results? Such as the cell inhibition expression of gastric adenocarcinoma cell lines.

2. The paper only studied the protein expression level by IHC staining, did you try by Western-blotting? Have you checked the mRNA expression level?

3. Needs some language corrections before being published. For example:

Page 7 line3: "…. Immunohistocheminal Analysis of EphA3 " Immunohistocheminal should be immunohistochemical.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal